On April 7, 2022, the Centers for Medicare & Medicaid Services (CMS) finalized their decision to limit coverage for monoclonal antibodies, such as Aduhelm (aducanumab), to only those who are enrolled in a randomized controlled trial. As this decision restricts access to this medication to patients with the means to cover the cost of treatment, Butler Hospital has suspended administration of this drug. The Memory and Aging Program (MAP) at Butler Hospital remains dedicated to making advances in the fight against Alzheimer’s disease and to offering patients and families the very best treatment options. We look forward to conducting trials with monoclonal antibodies in the future should the opportunity arise. Any updates on Butler’s use of Aduhelm in the future will be posted here. Please contact Biogen’s Alzheimer’s Support Services at 1-833-425-9360 to find other locations that currently offer Aduhelm.
You may be a candidate for treatment with Aduhelm if you have mild difficulty in memory and/or other thinking abilities. Those with a diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease may be eligible for treatment.
Aduhelm may not be a good fit for you if you have a history of stroke, are on anticoagulants (“blood thinners”), are unable to complete an MRI, or have more significant memory or thinking difficulties that impair your ability to perform daily tasks independently, such as running errands, cleaning your home, managing your finances, or driving.
Currently, we are not accepting referrals but will update this page as soon as we can offer this treatment.